Chief Executive Officer
Dr. Garry Neil serves as CEO of Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β therapies for immune-mediated inflammatory diseases, appointed in February 2022. He leads the advancement of AVTX-009 through Phase 2 trials for hidradenitis suppurativa, with data expected mid-2026